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M. Jahan, P. Wynn, B. Wang. EH Graham Centre for Agricultural Innovation,
Charles Sturt University, NSW, Australia
E-mail address: mjahan@csu.edu.au (M. Jahan)
Background/Aims: Human milk sialic acids has been proposed as a
bioactive compound promoting immune function, gut maturation and
neurodevelopment of the newborn. Porcine milk however, has received
little attention. The aims of the present study were to quantify and
compare the levels of N-acetylneuraminic acid (Neu5Ac), N-glycolylneur-
aminic acid (Neu5Gc) and ketodeoxynonulpsonic acid (KDN) in sow milk
during course of lactation.
Method:Milk samples from 22 sows were collected by manual expression
on 3 occasions, day 1 (colostrum), day 3 (transition milk) and day 15-21
(mature milk) respectively. The concent-ration of Neu5Ac, Neu5Gc and
KDN were analyzed using UHPLC.
Results: Sow milk contained signiﬁcant amounts of Sia with the highest
concentration found in colostrum (1238.50 mg/L) followed by transition
milk and then mature milk. Neu5Ac was the major form of Sia (93-96%)
and then Neu5Gc (3-6%), KDN however contained as little as 1-2%. This
distribution was common to each milk fraction and to each time point in
lactation.
Conclusions: Porcine milk contained a rich source of sialylated glyco-
conjugate. The predominately form of sialic acid is Neu5Ac. The high
concentrations of Sia in porcine milk suggest that Sia is an important
nutrient that may contribute to the optimization of immune function,
neuro-development and growth and development of piglets.
Funding source(s): International Postgraduate Research Scholarships,
Charles Sturt University.
MOLECULAR MECHANISMS DRIVING AIRWAY INFLAMMATION
FOLLOWING A HIGH-FAT MIXED MEAL IN ASTHMA
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Background/Aims: A high fat meal is associatedwith airway inﬂammation
in asthma, but the mechanisms are not well understood. This aim of this
study was to use microarray techniques to examine the molecular mech-
anisms of fat-induced airway inﬂammation in asthma compared with
healthy controls.
Methods: Subjects with asthma (n ¼ 11) and healthy controls (n ¼ 8)
were provided with a high-fat, high energy meal, containing total en-
ergy (TE) of 3846 kJ and 48 g (49% of TE) total fat, including 20.5 g (21%
of TE) saturated fat. Sputum was induced at 0 and 4 hours and gene
expression was examined by microarray and quantitative real-time PCR
(qPCR).
Results: Following the high fat dietary challenge, 168 entities were
signiﬁcantly differentially expressed greater than 1.5 fold in subjects with
asthma. Five genes involved in immune system processes were selected for
qPCR analysis (S100P, S100A16, MAL, MUC1 and NLPR12). qPCR conﬁrmed
that S100P, S100A16, MAL and MUC1 were signiﬁcantly increased in the
asthma group post-meal. There was a moderate and signiﬁcant correlation
between the change in S100P andMUC1 gene expression and the change in
sputum %neutrophils following the high fat meal (r ¼ 0.552, p ¼ 0.024; r ¼
0.495, p ¼ 0.045 respectively). NLRP12 gene expression at 4 hours strongly
correlated with the change in total and saturated non-esteriﬁed plasma
fatty acid levels at 2 hours (r ¼ 0.555, p ¼ 0.028; r ¼ 0.53, p ¼ 0.037
respectively).
Conclusions: Our data identiﬁes several genes that contribute to neutro-
philic airway inﬂammation following consumption of a high fat meal in
asthmatics, which may prove to be therapeutic targets for
immunomodulation.
Funding sources: NHMRC, HMRI, Thoracic Society of Australia and New
Zealand.DOES INCREASED INTAKE OF FOLIC ACID INCREASE CANCER RISK?
D. Mackerras, J. Tan, C. Larter. Food Standards Australia New Zealand, ACT,
Australia
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Background/Aims: Food Standards Australia New Zealand monitored the
literature regarding cancer risk following mandatory fortiﬁcation with
folic acid to reduce the risk of neural tube defects in Australia.
Methods: Randomised controlled trials testing folic acid for at least one
year and reporting any of: all-cause mortality, total cancer, four selected
cancers or recurrence of colorectal adenoma in healthy non-pregnant
adults were identiﬁed by searching in PubMed and CENTRAL from 2001
onwards. Random effects meta-analysis of the relative risks was conducted
using StatsDirect (http://www.statsdirect.co.uk).
Results: Twenty-six trials, lasting up to 7.3 years, were identiﬁed from
4216 abstracts. The larger trials generally described masked allocation
and blind outcome assessment. The 13 trials (43,557 subjects) reporting
total cancer incidence yielded a non-signiﬁcant overall relative risk (RR)
of 1.04 (95%CI: 0.97-1.11). Fewer studies reported results for colorectal
cancer RR ¼ 1.00 (95%CI: 0.82-1.23), breast cancer RR ¼ 0.82 (95%CI:
0.63-1.07), lung cancer RR¼ 1.00 (95%CI: 0.84-1.21) or prostate cancer RR
¼ 1.16 (95% CI: 0.85-1.60). Only the results for prostate cancer indicated
any heterogeneity (I2 ¼ 52.7%). Most data comes from large trials testing
0.8-2.5 mg/day.
Conclusions: There are no signiﬁcant increases or decreases in cancer risk.
Other meta-analyses using different inclusion criteria to select studies
have found similar results. The amount of folic acid used in mandatory
fortiﬁcation in Australia is about one-tenth of that tested and the effect on
blood folate levels has been commensurately lower.
Funding source(s): None.
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Background/Aims: Previously, we have reported that Emu Oil (EO)
lengthens intestinal crypts, a feature of intestinal growth, in experimental
colitis (2012) and mucositis (2013). However, it remains unclear whether
the crypt lengthening represents normal or aberrant intestinal growth. We
aimed to determine if crypt depth measurements in EO-treated rats
returned to normal levels following withdrawal of EO therapy.
Methods: Dark Agouti rats (n ¼ 8/group) were gavaged daily for 10 days
with Water, Olive Oil (OO) or EO (1ml) or 0.5 mL EO (0.5EO). Rats were
euthanized on day 10 or day 17. Intestinal weights, lengths, villus height
(VH) and crypt depth (CD) were quantiﬁed. P < 0.05 was considered
signiﬁcant.
Results: On day 10, jejuno-ileum (JI) weight was increased by OO (26%)
and EO (0.5mL: 15%; 1mL: 29%; p < 0.01), whichwas normalised by day 17.
On days 10 and 17, JI length was greater in OO- (12%) and EO-treated rats
(0.5 mL: 8%; 1 mL: 12%; p < 0.05), relative to water controls. On day 10, OO
and EO increased ileal VH (OO: 32%; 0.5EO: 22%; EO: 35%; p < 0.01) and CD
(OO: 17%; 0.5EO: 13%; EO: 22%); importantly however, after withdrawal of
all oils, VH and CD returned to normal levels. Moreover, the VH:CD ratio (a
feature of dysplasia) was unaffected in all oil-treated rats compared to
normal controls.
Conclusions: The restoration of normal intestinal growth following
cessation of Emu Oil therapy supports its safety for intestinal conditions.
Funding source(s): N/A.
DIETARY FISH OIL AT LOW INTAKES INCREASES DHA INCORPORATION
AND REDUCES LOW FREQUENCY FATIGUE IN RAT HINDLIMB
SKELETAL MUSCLE
